Objective To systematically review the diagnostic value of contrast-enhanced ultrasound for benign and malignant pancreatic masses. Methods By searching Cochrone liberary, PubMed, Embase, CNKI, Wanfang database and VIP database from establishment to 7 August 2017, all of the eligible articles which conformed to the inclusion and exclusion criteria were harvested. The methodological quality of each literature was evaluated by QUADAS tools. Statistical analysis was conducted by the Meta-Disc 1.4 software. Results A total of 20articles, 1356 cases were analyzed in this study. The pooled sensitivity, specificity, positive likelihood radio, negative likelihood ratio and diagnostic odds ratio of contrast-enhanced ultrasound in the diagnosis of benign and malignant pancreatic masses were 0.88 [95%CI (0.85, 0.90)], 0.73 [95%CI (0.69, 0.77)], 3.25 [95%CI (2.36, 4.48)], 0.18 [95%CI (0.13, 0.25)], 23.88 [95%CI (12.94, 44.09)], respectively. The AUC and Q* were 0.8985 and 0.8297. Significant heterogeneity was found between studies. The threshold effect was not the main source of heterogeneity. Conlusions Contrast-enhanced ultrasound is a valuable method in the diagnosis of benign and malignant pancreatic masses.